jkids210,
Good morning. My post to you wasn't really to answer your questions put to Stockboy. I had just noticed your inquiries and your post on what a friend said to you.
That aside, I am not 100 % positive that this company will succeed. And there are too many factors involved in the last 7 years to try and give you an idea why I have been buying shares all these years. I am not a scientist, especially in a cutting edge area of DNA research, so therefore you can assume that this is a gamble on this end.
Richard is somewhat of a geek. People need to get over that. His disposition has not kept him from keeping this company alive with such moves as the Biofrontera purchase and sale that made us a cool 7 million. Yes, he was an officer of that company, but that only helps. If you listen to his last presentation you will see he has a very good handle on financing for biotechs and is taking a global approach, which I find very relieving, as the American dollar and it's credit worthiness is in, let's say, "questionable reliability". If financing for an up-and-coming biotech is a risky business, it may be better to look for funds where the currency is strong.
I was here every day during the reverse split. I remember a lot of talk but I do know Frudakis didn't (and wasn't in the position to) emphatically promise no reverse. It doesn't matter anyway. There was no experienced CEO, DNAP financing was in the hands of sharks, and there was no other choice. You either trust Tony Frudakis or you don't. I do, and have never had a problem with that. And I have averaged down. I have also been buying the last two weeks at .0061 and now .006 every day, so I guess I am still averaging down.
We started a project with Moffitt several years ago. Too many coincidences have occurred that have led up to M2Gen. That is my reason for singling out Gomez. You and I both know how some agreements must be kept close to the sleeve, especially with large co's like Merck. There may be nothing there, but my opinion in there is. Tony said we were running genome work for 3 major companies. It goes on and on, but in the end, it is worth a half-cent bet to this guy. "If you don't have the gambling money stay out". I like the odds here compared to Las Vegas(and I have done good there too).
You can say the financing with Dutchess is a mess but you have no idea what it used to be like. It has improved markedly, in my opinion, yet DNAPrint is still at the mercy of not having large revenues, the basis for good financing.
It all comes down to the science. Will it sell and is it going to be usefull and applicable. Little signs from Trace genetics, Ellipsis, the FDA, and Moffitt tell me maybe so.
It's a bet. For sure.
But I like it.
Wish I could give you more, but as things come to me I will pass them on to you, O.K.?
Regards. And good luck to you.
News 
Market Data 
Discover 
AI
